The speedy approval of Lumakras could drive growth for years to come.
News & Analysis: Amgen
You won't be paying much of a premium for either of these dividend stocks.
Here's why you should consider buying into these two companies for the long run.
There are certainly some problem spots for the big biotech.
The near future looks concerning for these companies in three different sectors. But for long-term investors, that can create opportunities.
Despite disappointing results that missed expectations, progress with an important new cancer drug saved the day.
Nobody seemed impressed by the company's latest quarterly results.
COVID-19 continued to negatively impact the big biotech.
AMGN earnings call for the period ending March 31, 2021.
Amgen just bought Rodeo Therapeutics in a move that bolsters its drug candidate pipeline.